The global intravenous ibuprofen market, valued at USD 7.6 billion in 2024, is poised for substantial growth, with a projected CAGR of 8.6% from 2025 to 2034. This upward trajectory is driven by the ...

Both ibuprofen and naproxen potently inhibit hTAS1R2–TAS1R3 receptors that sense sweetness in a dose-dependent manner. The suppression of sugar signaling by ibuprofen and naproxen at physiological ...